Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Feb;27(2):221-6.
doi: 10.1080/07357900802208608.

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Jeanny B Aragon-Ching  1 , Yang-Min Ning, Clara C Chen, Lea Latham, Jean-Pierre Guadagnini, James L Gulley, Philip M Arlen, John J Wright, Howard Parnes, William D Figg, William L Dahut
Affiliations
Clinical Trial

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Jeanny B Aragon-Ching et al. Cancer Invest. 2009 Feb.

Abstract

ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient number 6 showing a negative bone scan upon study enrollment (A); Positive uptake over the left mandibular area appeared approximately 6 weeks prior to ONJ diagnosis (B); Increasing (worsening) uptake over the left mandibular area noted 4 months later (C); Improvement in the intensity noted after 4 months (D); Resolution and return to baseline 6 months later.
See this image and copyright information in PMC

References

    1. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol. 2007;62(2):148–152. - PubMed
    1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117. - PubMed
    1. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534. - PubMed
    1. Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gomez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12(4):E336–340. - PubMed
    1. Burr DB. Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact. 2007;7(4):354–355. - PubMed

Publication types